ary prophylaxis of venous thromboembolism (VTE) in males with prostate cancer in Sweden. Procedures: This

ary prophylaxis of venous thromboembolism (VTE) in males with prostate cancer in Sweden. Procedures: This population-based record-linkage cohort study used information from the National Prostate Cancer Register, the Prescribed Drug Registry and the Patient Registry in Sweden. We identified males having a initially VTE amongst 2013 and 2017 and described the form and duration of D2 Receptor Agonist drug outpatient anticoagulation they received. Final results: Amongst 1413 included guys, 96 began outpatient anticoagulant therapy inside four weeks after VTE diagnosis. Practically two-thirds (64 ) were prescribed parenteral anticoagulation, 31 a NOAC and 20 a VKA (males could obtain 1 kind of anticoagulant). Over the study period, use of parental anticoagulation declined from 83 to 53 , VKA use declined from 45 to four , and NOAC use increased from five to 51 . Men received their very first prescription inside 1 days immediately after their recorded VTE (median of 2 days). The median duration of use was 7 months (interquartile range [IQR] 33). A fifth of men had been dispensed three months anticoagulation, more than half (57 ) 6 months’ anticoagulation, and a quarter 1 year of anticoagulation. Duration was longer for pulmonary embolism (median 8 months, IQR 55) than for deep vein thrombosis (median 6 months, IQR 3). Conclusions: Men with prostate cancer and VTE in Sweden have been dispensed an typical of 7 months’ anticoagulation; however, a wide selection of remedy durations have been observed reflecting the individualised approach to Bradykinin B2 Receptor (B2R) Antagonist Accession treating VTE in these heterogeneous patients.PB1123|The use of DOACS in Catheter Related Thrombosis in Cancer U. Faruqi; G. Bahra; P.-L. Luo; Z. Mahir; A. Danaee Guys and St Thomas’ NHS Foundation Trust, London, Uk Background: At the moment, there is absolutely no consensus on the optimal management of catheter related upper extremity deep vein thrombosis826 of|ABSTRACT(UEDVT) in cancer patients. There’s increasing evidence for DOACs in cancer related thrombosis (CAT) but there is a paucity of data for the use of these agents in UEDVT. Aims: To describe a single centre practical experience around the use of DOAC in cancer individuals with catheter associated UEDVT. Procedures: Retrospective cohort study on the management of UEDVT in cancer individuals in between 2019 and 2020 at Guys and St Thomas’ Hospital London. Information was collected by reviewing electronic case notes and thrombosis confirmed on ultrasound doppler reports. Results: There had been 53 patients with UEDVT: 48 (90.5 ) PICC, 3 (five.6 ) portacath and two (3.7 ) cannula connected thrombosis. The PICC thromboses had been sub-analysed (Table 1). PICC lines had been in situ for any mean of 48.8 days (inter quartile variety 41.7 days) till thrombosis improvement. All patients were initiated on low molecular weight heparin (LMWH) till overview in CAT clinic when anticoagulation was converted to DOAC in 20 individuals (43.7 ) right after threat assessment. Two sufferers (9.five ) reported bleeding on DOACs. 1 minor bleeding and 1 clinically relevant non-major bleeding event with epistaxis requiring attendance to hospital. Bleeding was defined as per the ISTH criteria. There were no recurrent line thromboses on anticoagulation with DOACs or LMWH. Three patients developed recurrent thromboses on DOACS (1 superficial vein, two PE) and two sufferers on LMWH (one superficial vein, one PE). 13 (27 ) individuals continued DOAC prophylaxis following three months treatment dose with no recurrent line thrombosis. TABLE 1 Baseline demographics of sufferers presenting with PICC associated UEDVTConclusions: While this can be a sm